Special Issue

mRNA Therapeutics for Cancer Treatment

Message from the Guest Editors

Our Special Issue seeks original research articles and reviews that delve into various aspects of mRNA therapeutics for cancer, including but not limited to:

- mRNA-based cancer vaccines: explore the development and mechanisms of personalized mRNA vaccines tailored to individual tumor profiles, and their potential to induce targeted immune responses against cancer cells;
- Clinical insights: share the latest findings from clinical trials and studies evaluating the efficacy and safety of mRNA-based cancer therapies, shedding light on their real-world applications;
- Synergy with existing treatments: investigate the potential synergy between mRNA therapies and other established cancer treatment modalities, such as immunotherapy and targeted therapies, to maximize patient outcomes;
- Innovations in delivery: highlight advancements in mRNA delivery technologies, including lipid nanoparticles and other innovative approaches, that enhance the precision and effectiveness of cancer therapeutics;
- Future directions: discuss the future directions and challenges in the field of mRNA therapeutics for cancer treatment, identifying promising avenues for further research.

Guest Editors

Dr. Fatemeh Movahedi

Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD 4067, Australia

Prof. Dr. Chengzhong Yu

Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD 4072, Australia

Deadline for manuscript submissions

closed (31 December 2024)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/192055

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

